Low molecular weight (LMW) heparins have prolonged circulating half-lives relative to unfractionated heparin, but the rates of plasma clearance differ between different LMW preparations. To determine the impact of method of production on their pharmacokinetic and ex vivo biological properties, two LMW heparins of similar molecular weight distribution, Logiparin and Fragmin, were radiolabelled with 125I, administered intravenously with 4 mg/kg of carrier drug into rabbits, and the circulating radiolabelled material and anti-Xa activity were analysed by size exclusion chromatography and affinity for antithrom#bin and Polybrene. Following administration of Logiparin, the anti-Xa amidolytic activity was eliminated with the same half-life as the anti#thrombin-binding radiolabel and was not neutralised by antibody against tissue factor pathway inhibitor (TFPI). Larger molecules were cleared preferentially and were no longer detectable 8 h post injection. These findings resemble those we have previously described for Enoxaparin. After Fragmin administration the antithrombin binding radiolabel was cleared more rapidly than the anti-Xa activity, and at late times after injection a significant amount of this activity was neutralised by antibody against TFPI. Sulphated radiolabel was eliminated with a similar half-life to the anti-Xa activity and sulphated molecules >6000 Da remained in the circulation 8 h after administra#tion. Fragmin, unlike Logiparin and Enoxaparin, has no negatively charged sulphamino group at the reducing end of the molecule. We sug#gest that this minimises cellular interaction and protects the larger molecules from elimination. They remain in the circulation, contributing to anti-Xa activity by binding TFPI. Thus the method of production of LMW heparins may significantly influence their pharmacokinetic properties and circulating anticoagulant activities.
References
1
Dawes J,
Pepper D.
Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
4
Doutrempuich C,
Guyot M,
Lalanne M,
Deharo E,
Walenga J,
Fareed J.
Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects. Thromb Res 1989; 55: 419-426
7
Dawes J,
Prowse C,
Pepper D.
The measurement of heparin and other therapeutic sulphated polysaccharides in plasma serum and urine. Thromb Haemost 1985; 54: 630-634
9
Andersson L,
Barrowcliffe T,
Holmer E,
Johnson E,
Sims G.
Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 09: 575-583
10
Hodson B,
Pepper D,
Dawes J.
Novel affinity chromatographic system for the single step purification of glycosaminoglycans from complex systems using volatile buffers. J Chromatog 1991; 565: 416-423
11
Teien A,
Lie M.
Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
13
Østergaard P,
Nilsson B,
Bergquist D,
Hedner U,
Pedersen P.
The effect of low molecular weight heparin on experimental thrombosis and haemostasis – the influence of production metho. Thromb Res 1987; 45: 739-749
17
Bara L,
Billaud B,
Gramond G,
Kher A,
Samama M.
Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-636
18
Bratt G,
Tomebohm E,
Lockner D.
Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-619
19
Matzsch T,
Bergqvist D,
Hedner U,
Øtsergaard P.
Effects of an enzymati#cally depolymerised heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 097-101
21
Bregengaard C,
Nordfang O,
Østergaard P,
Petersen J,
Meyn G,
Diness V,
Svendsen O,
Hedner U.
Pharmacokinetics of full length and two domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-457
22
Lamkjoer A,
Østergaard P,
Flodgaard H.
Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro. Thromb Res 1994; 75: 185-194
23
van RijnJ,
Trillou M,
Mardiguian J,
Tobelem G,
Caen J.
Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211-222
24
Palm M,
Mattsson C.
Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-935
26
Valentin S,
Larnkjor A,
Østergaard P,
Nielsen J,
Nordfang O.
Characterisation of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-183
